ALKSAlkermes plc
Is it safe?
Nothing alarming, nothing pristine: insiders quiet, comfortable debt (A), and typical volatility.
Insiders were net sellers (-$3.8M, 90 days to Oct 8, 2026), selling is often routine.
Investment-grade balance sheet. A rule of thumb on leverage, not a credit rating.
Moderate price swings, typical volatility. Worst drawdown -81% · now 23% below its 52-week high.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can ALKS take a bad year?
Alkermes plc carries $847M of net debt at 5.19× EBITDA: a heavy load to carry through a bad year.
Net debt · as at Q2 2026 · over four years of earnings before interest, tax and depreciation, heavy
- Net debt / EBITDA
- 5.19×
Net debt / EBITDA
- Interest cover
- 1.98×
Interest cover · operating profit barely covers the interest bill
- Annualised volatility
- 38%
Annualised volatility · roughly twice as jumpy as the market
Details›
- Total debtQ2 2026
- $1.50B
- Cash and short-term investments
- $657M
- Net debt
- $847M
- EBITDA, trailing twelve months
- $163M
- Operating profit, trailing twelve months
- $117M
- Debt / equity
- 0.83×
- Total debt / EBITDA
- 9.21×
- Annualised volatilitytwo years of daily moves
- 38%
- Worst drawdown on file
- −81%
- Below its 52-week high
- 23%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Drug Manufacturers, Specialty & Generic
Ranks #17 of 41 by RyuScore